Department of Chemistry, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan.
Forefront Research Center, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan.
Int J Mol Sci. 2023 May 31;24(11):9593. doi: 10.3390/ijms24119593.
Targeted alpha therapy (TAT) has garnered significant interest as an innovative cancer therapy. Owing to their high energy and short range, achieving selective α-particle accumulation in target tumor cells is crucial for obtaining high potency without adverse effects. To meet this demand, we fabricated an innovative radiolabeled antibody, specifically designed to selectively deliver At (α-particle emitter) to the nuclei of cancer cells. The developed At-labeled antibody exhibited a superior effect compared to its conventional counterparts. This study paves the way for organelle-selective drug delivery.
靶向α治疗（TAT）作为一种创新性的癌症治疗方法引起了广泛关注。由于α粒子具有高能量和短射程的特点，因此实现选择性的α粒子在靶肿瘤细胞中的积累对于获得高疗效而无不良反应至关重要。为了满足这一需求，我们制备了一种创新的放射性标记抗体，专门设计用于将 At（α粒子发射体）选择性递送到癌细胞的核内。与传统的抗体相比，所开发的 At 标记抗体表现出更好的效果。这项研究为细胞器选择性药物递送铺平了道路。
